港股医药股今日遭遇重挫,其中药明生物盘中一度大跌8.85%报24.600港元。这一跌幅引发了市场广泛关注。
有分析认为,导致药明生物股价大跌的主要原因可能与美国拟限制中国企业在某些战略领域的投资有关。据报道,美国总统特朗普签署备忘录,要求相关部委限制包括中国在内的国家对美国若干战略领域进行投资。同时还指示不同部门制订新法例,限制美资在中国参与敏感领域的投资。
作为中国领先的服务于生物制药行业的企业之一,药明生物的业务或会受到一定影响。业内人士表示,如果相关政策落实,将对该公司在美国的业务拓展带来潜在阻力,进而影响全球业务布局规划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.